ea0029p824 | Endocrine tumours and neoplasia | ICEECE2012
Zsippai A.
, Szabo D.
, Tombol Z.
, Szabo P.
, Eder K.
, Patocs A.
, Toth S.
, Falus A.
, Racz K.
, Igaz P.
Background: The adrenolytic agent mitotane is widely used in the adjuvant treatment of adrenocortical cancer, but its mechanism of action including potential effects on mRNA expression is poorly elucidated.Objective: To examine mitotane-induced mRNA expression changes in the H295R adrenocortical cancer cell line.Methods: Various concentrations of mitotane in different treatment periods (24120 h) have been tested in cell viabi...